Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 12/20 | 0.48 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3960558 | 1.00 | MRGPRX4 (0.48) | MRGPRX4RXRAPTGER1POLBMAPT | |
| Hydrochloric Acid SCHEMBL1354482 | 0.99 | MRGPRX4 (0.47) | MRGPRX4RXRAPTGER1POLBMAPT | |
| Hydrochloric Acid SCHEMBL723194 | 0.99 | MRGPRX4 (0.47) | MRGPRX4RXRAPTGER1POLBMAPT | |
| SCHEMBL1901761 | 0.91 | HPGD (0.42) | MRGPRX4RXRAPOLBMAPTTHRB | |
| SCHEMBL7752289 | 0.91 | HPGD (0.42) | MRGPRX4RXRAPOLBMAPTTHRB | |
| SCHEMBL2634518 | 0.85 | CHRM2 (0.43) | MRGPRX4MAPTGLRA1SMN1; SMN2NPC1 | |
| SCHEMBL7756337 | 0.85 | CHRM2 (0.43) | MRGPRX4MAPTGLRA1SMN1; SMN2NPC1 | |
| SCHEMBL722893 | 0.85 | CHRM2 (0.43) | MRGPRX4MAPTGLRA1SMN1; SMN2NPC1 | |
| SCHEMBL19212506 | 0.85 | KDM4E (0.40) | RXRAPOLBMAPTSMN1; SMN2NPC1 | |
| SCHEMBL724698 | 0.83 | CHRM2 (0.45) | RXRAPOLBMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | disclosed |
| US-20130197260-A1 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | CADILA HEALTHCARE LIMITED (IN) | 2013-08-01 | — | — | US | disclosed |
| WO-2012025941-A2 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | CADILA HEALTHCARE LIMITED (IN) | 2012-03-01 | — | — | WO | disclosed |
| US-6809225-B2 | BY HYDROCARBONYLATION/HYDROFORMYLATION WITH SUBSEQUENT REDUCTIVE AMINATION | SCHWARZ PHARMA AG (DE) | 2004-10-26 | — | — | US | disclosed |
| US-20040034080-A1 | Method for producing 3,3-diarylpropylamines | UCB PHARMA GMBH (DE) | 2004-02-19 | — | — | US | disclosed |
| EP-1077912-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058478-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197260-A1 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | QDPR, FES, SULT1A1 | MRGPRX4 1996/4885RXRA 3039/4885PTGER1 2728/4885 |
| US-20040034080-A1 | Method for producing 3,3-diarylpropylamines | HNMT, CYP1A1, HRH3 | MRGPRX4 1545/4885RXRA 3925/4885PTGER1 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.